Compare · ATHE vs RUBY
ATHE vs RUBY
Side-by-side comparison of Alterity Therapeutics Limited (ATHE) and Rubius Therapeutics Inc. (RUBY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ATHE focuses on Biotechnology: Pharmaceutical Preparations, while RUBY focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- RUBY is the larger of the two at $574.2M, about 9.6x ATHE ($59.9M).
- ATHE has hit the wire 5 times in the past 4 weeks while RUBY has been quiet.
- RUBY has more recent analyst coverage (4 ratings vs 3 for ATHE).
- Company
- Alterity Therapeutics Limited
- Rubius Therapeutics Inc.
- Price
- $3.91-2.49%
- $0.09-26.81%
- Market cap
- $59.9M
- $574.2M
- 1M return
- -14.44%
- -
- 1Y return
- -18.20%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 0
- Recent ratings
- 3
- 4
Alterity Therapeutics Limited
Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.
Rubius Therapeutics Inc.
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Latest ATHE
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
- SEC Form 6-K filed by Alterity Therapeutics Limited
- Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
- SEC Form 6-K filed by Alterity Therapeutics Limited
Latest RUBY
- SEC Form 15-12G filed by Rubius Therapeutics Inc.
- SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)
- Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 25 filed by Rubius Therapeutics Inc.
- SEC Form DEF 14A filed by Rubius Therapeutics Inc.
- Stocks That Hit 52-Week Lows On Monday
- Why Aclaris Therapeutics Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- 12 Health Care Stocks Moving In Monday's Intraday Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Hertz Global Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket